Study on prolonged infusion administration improve the meropenem therapeutic effects in critical patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003565

Enrollment

Unknown

Registered

2013-08-17

Start date

2013-10-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infection

Interventions

Study Group:Prolong infusion time to 3hr

Control:Bolus Intermittent Infusion in 30min

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Aged >18 years; no Carbapenem allergy; Need Meropenem therapy; Informed consent;

Exclusion criteria

Exclusion criteria: Carbapenem allergy; Pregnancy or lactation; Renal dysfunction with Ccr<50mL/min.

Design outcomes

Primary

Measure	Time frame
Therapeutic Effect;Pharmacoeconomicos;	—

Secondary

Measure	Time frame
Bacteriology;inconography;	—

Countries

China

Contacts

Public ContactDawei Wu

wdw.55@163.com+86 13791122767

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026